And its European Medicines Company equivalent, the Hybrid Program, in Europe.’.. Chiasma presents Octreolin pharmacology data from clinical studies at International Pituitary Congress Chiasma, Inc., a kept biopharma company privately, presented pharmacology results from clinical studies at the 12th International Pituitary Congress showing that Octreolin, a proprietary investigational new oral formulation of octreotide, demonstrated a consistent pharmacokinetic profile similar compared to that of subcutaneously injected octreotide acetate.Â Â.
CDP commends Pfizer for addressing environment change practices Pfizer Inc offers been commended by the Carbon Disclosure Project for its method of addressing climate modification. This is actually the third consecutive 12 months that Pfizer has been acknowledged by CDP. From 2002 to 2008, Pfizer decreased its global greenhouse gas emissions by 18 %; between 2008 and 2012, the business is committed to decrease those emissions by another 20 %. Companies are scored on their climate change disclosure, and high scores indicate good internal data management and understanding of climate change related issues affecting the company.
Cancer Cell publishes a paper on ARIAD Pharmaceuticals’ Pan-BCR-ABL inhibitor ARIAD Pharmaceuticals, Inc.